DACHS - IMPACT - Prognosis

Despite improvements in treatment of colorectal cancer (CRC), patient variability in treatment outcome is still frequently observed. Treatment outcome mainly depends on stage at diagnosis but there is also major variation in prognosis within groups of patients with the same tumor stage which is largely unexplained. Surgery is the primary treatment in CRC. According to CRC stage, patients may receive radiation or chemotherapy in advance or after surgery. Up to now, seven chemotherapeutic agents are approved in Germany. Individual differences in treatment outcome are observed and it is assumed that multiple genetic variants are involved in determining interindividual differences of CRC patients in response to therapy and in survival.

Aim of the project is to assess associations between different genetic variants and
(i) overall survival as well as
(ii) occurrence of relapse (progression-free survival) overall and differentiated by different treatment schemes.

Collaboration: Division of Clinical Epidemiology and Aging Research, DKFZ, Heidelberg
This project involves patients of the DACHS study and is part of a network investigating long-term prognosis in colorectal cancer patients called IMPACT (improving long-term prognosis and quality of life of patients with colorectal cancer).

Funding: German Federal Ministry of Education and Research (BMBF).

to top